BCDTs such as those targeting CD20, CD19, and BAFF are widely used in the treatment of autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. This evidence concerns the gene CD19 and systemic lupus erythematosus.